EBS vs SIGA
EBS: Emergent BioSolutions is a specialized biopharmaceutical firm that provides critical medical countermeasures and manufacturing services to protect against global public health threats and opioid overdose emergencies. SIGA: SIGA is a biodefense-focused pharmaceutical company selling tecovirimat (TPOXX®), an FDA-approved smallpox antiviral, primarily to the U.S. Strategic National Stockpile and international governments.
Side-by-side fundamentals
| Metric | EBS | SIGA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.58 | $3.39 | |
| Market cap as of 2026-07-23 | $393M | $242M | |
| P/E as of 2026-07-23 | 7.47 | 11.96 | EBS lower |
| Net margin as of 2026-07-23 | -1.3% | +21.6% | SIGA higher |
| Gross margin as of 2026-07-23 | +54.3% | +65.4% | SIGA higher |
| Operating margin as of 2026-07-23 | +9.0% | +22.0% | SIGA higher |
| ROE as of 2026-07-23 | -1.6% | +10.6% | SIGA higher |
| ROA as of 2026-07-23 | -0.6% | +8.9% | SIGA higher |
| Debt / equity as of 2026-07-23 | 1.10 | 0.00 | SIGA lower |
| Revenue growth (YoY) as of 2026-07-23 | -29.9% | -22.1% | SIGA higher |
| Revenue CAGR (3y) SEC XBRL | -12.7% | -5.1% | SIGA higher |
| Dividend yield as of 2026-07-23 | n/a | +17.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-07-23 | 2.40 | 0.91 | |
| 1-year return as of 2026-07-22 close | +10.2% | -47.7% | EBS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.